| Literature DB >> 35004985 |
Rong-Yu Zhu1, Si-Qu Xiang1, Dou-Ren Chen2.
Abstract
BACKGROUND: Laparoscopic surgery has become a common surgical approach for the clinical treatment of intra-abdominal lesions in recent years. We hypothesized that lumbar block with postoperative patient-controlled intravenous analgesia (PCIA) by butorphanol after gynecological surgery under general anesthesia would be more effective than PCIA by butorphanol alone. AIM: To investigate the effect of lumbar block with PCIA by butorphanol after gynecological surgery under general anesthesia.Entities:
Keywords: Analgesic effect; Butorphanol; Patient-controlled intravenous analgesia; Quadratus lumborum block
Year: 2021 PMID: 35004985 PMCID: PMC8686127 DOI: 10.12998/wjcc.v9.i34.10540
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Comparison of general data between the two groups
|
|
|
|
|
|
| Age (yr) | 57.7 ± 7.8 | 55.8 ± 7.1 | 1.395 | 0.166 |
| Weight (kg) | 55.9 ± 5.4 | 57.0 ± 6.1 | -1.046 | 0.298 |
| Height (cm) | 158.9 ± 5.2 | 159.6 ± 6.0 | -0.683 | 0.496 |
| Systolic pressure (mmHg) | 122.4 ± 8.4 | 121.3 ± 7.0 | 0.779 | 0.437 |
| Diastolic pressure (mmHg) | 74.1 ± 6.0 | 75.6 ± 7.5 | -1.210 | 0.229 |
| Heart rate (times/min) | 81.5 ± 8.0 | 80.4 ± 8.5 | 0.730 | 0.467 |
| Operation time (min) | 105.7 ± 16.4 | 107.1 ± 20.0 | -0.419 | 0.676 |
| Anesthesia time (min) | 124.8 ± 15.0 | 126.4 ± 14.3 | -0.598 | 0.551 |
| ASA grade, | 0.616 | 0.432 | ||
| I | 39 (65.00) | 43 (71.67) | ||
| II | 21 (35.00) | 17 (28.33) | ||
| Diabetes, | 2.596 | 0.107 | ||
| Yes | 11 (18.33) | 5 (8.33) | ||
| No | 49 (81.67) | 55 (91.67) | ||
| Coronary heart disease, | 1.081 | 0.298 | ||
| Yes | 3 (5.00) | 6 (10.00) | ||
| No | 57 (95.00) | 54 (90.00) | ||
| Dyslipidemia, | 1.677 | 0.195 | ||
| Yes | 11 (18.33) | 17 (28.33) | ||
| No | 49 (81.67) | 43 (71.67) | ||
| Disease type, | 3.597 | 0.308 | ||
| Fibroid | 22 (36.67) | 30 (50.00) | ||
| Cervical carcinoma | 16 (26.67) | 10 (16.67) | ||
| Endometrial carcinoma | 12 (20.00) | 8 (13.33) | ||
| Others | 10 (16.67) | 12 (20.00) |
Comparison of visual analog scale scores of postoperative analgesia between the two groups (mean ± SD, points)
|
|
|
|
|
|
|
| At resting state | |||||
| Study group ( | 2.29 ± 0.59 | 2.78 ± 0.81 | 2.90 ± 0.78 | 2.45 ± 0.65 | 1.75 ± 0.63 |
| Control group ( | 2.15 ± 0.52 | 3.07 ± 0.85 | 3.31 ± 0.88 | 2.81 ± 0.74 | 1.90 ± 0.50 |
|
| 1.379 | -1.913 | -2.701 | -2.831 | -1.445 |
|
| 0.171 | 0.058 | 0.008 | 0.005 | 0.151 |
| At cough state | |||||
| Study group ( | 2.50 ± 0.64 | 3.10 ± 0.75 | 3.08 ± 0.81 | 2.94 ± 0.86 | 2.26 ± 0.78 |
| Control group ( | 2.37 ± 0.59 | 3.54 ± 0.88 | 3.51 ± 0.89 | 3.12 ± 0.90 | 2.43 ± 0.83 |
|
| 1.157 | -2.948 | -2.768 | -1.120 | -1.156 |
|
| 0.250 | 0.004 | 0.007 | 0.265 | 0.250 |
VAS: Visual analog scale.
Comparison of inflammatory factor levels at different times after operation between the two groups (mean ± SD)
|
|
|
|
|
| TNF-α (pg/mL) | |||
| Study group ( | 161.5 ± 27.5 | 228.5 ± 32.4 | 230.6 ± 35.1 |
| Control group ( | 157.8 ± 25.3 | 242.7 ± 29.6 | 238.2 ± 31.8 |
|
| 0.767 | -2.506 | -1.243 |
|
| 0.445 | 0.014 | 0.216 |
| IL-6 (pg/mL) | |||
| Study group ( | 51.77 ± 6.83 | 89.47 ± 9.20 | 83.65 ± 8.11 |
| Control group ( | 54.02 ± 8.16 | 95.71 ± 10.36 | 97.20 ± 9.54 |
|
| -1.638 | -3.489 | -8.382 |
|
| 0.104 | 0.001 | 0.000 |
| IL-8 (pg/mL) | |||
| Study group ( | 71.5 ± 13.9 | 94.6 ± 18.6 | 88.2 ± 15.7 |
| Control group ( | 73.6 ± 12.5 | 102.5 ± 20.4 | 97.8 ± 16.4 |
|
| -0.870 | -2.217 | -3.275 |
|
| 0.386 | 0.029 | 0.001 |
IL: Interleukin; TNF-α: Tumor necrosis factor-alpha.
Comparison of patient-controlled intravenous analgesia compression times at different times after operation between the two groups (mean ± SD, times)
|
|
|
|
|
|
| Study group | 60 | 1.47 ± 0.60 | 2.18 ± 0.56 | 2.64 ± 0.62 |
| Control group | 60 | 3.13 ± 1.02 | 4.30 ± 0.94 | 4.16 ± 0.90 |
|
| -10.866 | -15.008 | -10.773 | |
|
| 0.000 | 0.000 | 0.000 |
Ramsay score comparison of two groups at different times after operation (mean ± SD, points)
|
|
|
|
|
|
| Study group | 60 | 2.40 ± 0.57 | 2.33 ± 0.60 | 2.18 ± 0.56 |
| Control group | 60 | 2.57 ± 0.61 | 2.50 ± 0.74 | 2.31 ± 0.68 |
|
| -1.577 | -1.382 | -1.143 | |
|
| 0.117 | 0.170 | 0.255 |
Comparison of related adverse reactions between the two groups, n (%)
|
|
|
|
|
|
|
|
| Study group | 60 | 3 (5.00) | 1 (1.67) | 0 (0.00) | 1 (1.67) | 1 (1.67) |
| Control group | 60 | 11 (18.33) | 2 (3.33) | 2 (3.33) | 7 (11.67) | 3 (5.00) |
|
| 5.175 | 0.342 | 2.034 | 4.821 | 1.034 | |
|
| 0.023 | 0.559 | 0.154 | 0.028 | 0.309 |